Skip to main content
Top
Published in: International Urology and Nephrology 4/2009

01-12-2009 | Urology - Original Paper

Clinical symptoms related to renal cell carcinoma are independent prognostic factors for intraoperative complications and overall survival

Authors: Attila Szendrői, Ádám Tabák, Peter Riesz, Miklós Szűcs, Peter Nyírády, Attila Majoros, Gabriel Haas, Imre Romics

Published in: International Urology and Nephrology | Issue 4/2009

Login to get access

Abstract

Objective

It is not yet elucidated whether the symptoms related to renal cell carcinoma have a strong effect on intraoperative complications or survival. We aimed to investigate this association in a cohort of renal cancer patients operated on between June 1997 and December 2004 at the Department of Urology, Semmelweis University School of Medicine.

Patients and methods

Among 363 consecutive patients with renal masses treated at our institution, only 200 (55.3%) were truly asymptomatic and completely incidental (group A). Among the 259 patients with incidentally detected tumors, 59 (16.1%) had symptoms that were probably related to the renal lesion according to a reviewed history (group B) and 104 patients (28.6%) presented for symptoms related to renal cell cancer (group C).

Results

Patients in group B had a higher risk for weight loss (P < 0.0001) and flank pain (P = 0.063), lower risk for symptoms related to distant metastases, while their outcome was not significantly different from group C. The collapsed group (B + C) had an increased risk for metastasis (P = 0.002), higher stage (P = 0.001), and intraoperative complications (P = 0.046) compared to group A according to a logistic regression. The presence of symptoms was significantly related to the overall survival using the Kaplan–Meier method (P < 0.0001).

Conclusions

Weight loss and flank pain were frequently neglected as a possible symptom of renal cancer by the patients. An easily accessible parameter (the presence of symptoms) was independently related to intraoperative complications and survival in renal cancer patients.
Literature
1.
2.
go back to reference Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 167:57–60CrossRefPubMed Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 167:57–60CrossRefPubMed
3.
go back to reference Lovász S, Romics I (1998) Interleukin-2 (IL”) terápia a metasztatizáló veserák kezelésében. In: Romics I, Goepel M (eds) A here és vesedaganatok diagnosztikája és terápiája, 1st edn. Akadémiai Kiadó Budapest, Hungary Lovász S, Romics I (1998) Interleukin-2 (IL”) terápia a metasztatizáló veserák kezelésében. In: Romics I, Goepel M (eds) A here és vesedaganatok diagnosztikája és terápiája, 1st edn. Akadémiai Kiadó Budapest, Hungary
4.
go back to reference Touloupidis S, Papathanasiou A, Kalaitzis C et al (2006) Renal cell carcinoma: the influence of new diagnostic imaging techniques on the size and stage of tumors diagnosed over the past 26 years. Int Urol Nephrol 38(2):193–197. doi:10.1007/s11255-005-4762-4 CrossRefPubMed Touloupidis S, Papathanasiou A, Kalaitzis C et al (2006) Renal cell carcinoma: the influence of new diagnostic imaging techniques on the size and stage of tumors diagnosed over the past 26 years. Int Urol Nephrol 38(2):193–197. doi:10.​1007/​s11255-005-4762-4 CrossRefPubMed
7.
go back to reference Ficarra V, Prayer-Galetti T, Novella G et al (2003) Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 43:663–669PubMed Ficarra V, Prayer-Galetti T, Novella G et al (2003) Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 43:663–669PubMed
11.
go back to reference Wotkowicz C, Libertino JA (2007) Renal cell cancer: radical nephrectomy. Br J Urol Int 99:1231–1238 Wotkowicz C, Libertino JA (2007) Renal cell cancer: radical nephrectomy. Br J Urol Int 99:1231–1238
17.
go back to reference Lam JS, Breda A, Belldegrun AS et al (2006) Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 35:5556–5575 Lam JS, Breda A, Belldegrun AS et al (2006) Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 35:5556–5575
20.
go back to reference Hellsten S, Johnsen J, Berge T et al (1990) Clinically unrecognized renal cell carcinoma. Diagnostic and pathological aspects. Eur Urol 18(Suppl 2):2–3PubMed Hellsten S, Johnsen J, Berge T et al (1990) Clinically unrecognized renal cell carcinoma. Diagnostic and pathological aspects. Eur Urol 18(Suppl 2):2–3PubMed
22.
go back to reference Patard JJ, Rodriguez A, Rioux-Leclercq N et al (2002) Prognostic significance of the mode of detection in renal tumours. Br J Urol Int 90:358–363 Patard JJ, Rodriguez A, Rioux-Leclercq N et al (2002) Prognostic significance of the mode of detection in renal tumours. Br J Urol Int 90:358–363
24.
go back to reference Pajor L, Kisbenedek L, Buzogány I et al (2003) A felnőttkori vesedaganatok kezelése (Módszertani levél). Mol Urol 15:4 Pajor L, Kisbenedek L, Buzogány I et al (2003) A felnőttkori vesedaganatok kezelése (Módszertani levél). Mol Urol 15:4
25.
go back to reference Park WH, Eisen T (2007) Prognostic factors in renal cell cancer. Br J Urol Int 99:1277–1281 Park WH, Eisen T (2007) Prognostic factors in renal cell cancer. Br J Urol Int 99:1277–1281
26.
go back to reference Knight DA, Stadler WM (2007) Prognostic factors in localized renal cell cancer. Br J Urol Int 99:1212–1216 Knight DA, Stadler WM (2007) Prognostic factors in localized renal cell cancer. Br J Urol Int 99:1212–1216
27.
go back to reference Ng CF, Wan SH, Wong A et al (2007) Use of the University of California Los Angeles Integrated Staging System (UISS) to predict survival in localized renal cell carcinoma in an Asian population. Int Urol Nephrol 39(3):699–703. doi:10.1007/s11255-006-9134-1 CrossRefPubMed Ng CF, Wan SH, Wong A et al (2007) Use of the University of California Los Angeles Integrated Staging System (UISS) to predict survival in localized renal cell carcinoma in an Asian population. Int Urol Nephrol 39(3):699–703. doi:10.​1007/​s11255-006-9134-1 CrossRefPubMed
29.
go back to reference Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395–2400. doi:10.1016/S0022-5347(05)64153-5 CrossRefPubMed Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395–2400. doi:10.​1016/​S0022-5347(05)64153-5 CrossRefPubMed
Metadata
Title
Clinical symptoms related to renal cell carcinoma are independent prognostic factors for intraoperative complications and overall survival
Authors
Attila Szendrői
Ádám Tabák
Peter Riesz
Miklós Szűcs
Peter Nyírády
Attila Majoros
Gabriel Haas
Imre Romics
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2009
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9539-8

Other articles of this Issue 4/2009

International Urology and Nephrology 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.